Ranbaxy Laboratories has reported results for fourth quarter and year ended December 31, 2012.
The company has reported a net loss of Rs 616.09 crore for the quarter ended December 31, 2012 as compared to a net loss of Rs 2710.32 crore for the same quarter in the previous year. Total income of the company has decreased by 61.61% at Rs 1508.63 crore for quarter under review as compared to Rs 3930.35 crore for the quarter ended December 31, 2011.
On consolidated basis, the company has reported a net loss of Rs 492.44 crore for the quarter ended December 31, 2012 as compared to a net loss of Rs 2982.76 crore for the same quarter in the previous year. Total income of the company has decreased by 27.95% at Rs 2787.88 crore for quarter under review as compared to Rs 3869.38 crore for the quarter ended December 31, 2011.
For the fiscal 2012, the company has reported a net loss of Rs 162.33 crore for the year ended December 31, 2012 as compared to a net loss of Rs 3052.04 crore for the same in the previous year. Total income from operations went down by 16.38% to Rs 6543.14 crore from Rs 7825.19 crore in last year.
For the entire fiscal, on consolidated basis the company has reported a net profit of Rs 922.76 crore for the year ended December 31, 2012 as compared to a net loss of Rs 2899.72 crore for the same in the previous year. Total consolidated income from operations went up by 22.74% to Rs 12732.89 crore from Rs 10373.92 crore in last year.
